Replies to post #90616 on Biotech Values

[DewDiligence]

SNY formally kills the Otamixaban (oral FXa-inhibitor) program, which is not surprising. Like PTLA’s Betrixaban (which is still in development but shouldn’t be, IMO), Otamixaban was too little, too late to compete with the likes of Eliquis and Xarelto.